MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Tekmira Pharmaceuticals Corp Company Profile (NASDAQ:ABUS)

Consensus Ratings for Tekmira Pharmaceuticals Corp (NASDAQ:ABUS) (?)
Ratings Breakdown: 1 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $12.05 (258.63% upside)

Analysts' Ratings History for Tekmira Pharmaceuticals Corp (NASDAQ:ABUS)
Show:
DateFirmActionRatingPrice TargetActions
6/16/2016Chardan CapitalUpgradeSell -> Neutral$3.25View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2016Leerink SwannReiterated RatingBuy$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016WedbushReiterated RatingOutperform$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/21/2015RBC CapitalLower Price Target$20.00 -> $12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/2/2015JMP SecuritiesInitiated CoverageOutperform$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/16/2015Maxim GroupLower Price TargetHold -> Buy$27.00 -> $14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/30/2015NomuraInitiated CoverageBuy$32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/7/2014Stifel NicolausReiterated RatingPositive -> Buy$31.00 -> $26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/31/2014Clarus SecuritiesInitiated CoverageBuy$22.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for Tekmira Pharmaceuticals Corp (NASDAQ:ABUS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/4/2016Q1($0.39)($0.19)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/9/2016Q4($0.41)($0.06)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015($0.31)($0.42)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q2($0.26)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/13/2015($0.32)($0.27)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q314($0.31)($0.39)$3.71 million$4.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2014Q214($0.26)($0.28)$3.72 million$1.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
12/18/2013Q3($0.07)($0.12)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Tekmira Pharmaceuticals Corp (NASDAQ:ABUS)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.38)($0.36)($0.37)
Q2 20162($0.40)($0.35)($0.38)
Q3 20162($0.41)($0.39)($0.40)
Q4 20162($0.39)($0.36)($0.38)
(Data provided by Zacks Investment Research)
Dividend History for Tekmira Pharmaceuticals Corp (NASDAQ:ABUS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Tekmira Pharmaceuticals Corp (NASDAQ:ABUS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
8/24/2015Richard C Henriques JrDirectorBuy1,000$6.95$6,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Tekmira Pharmaceuticals Corp (NASDAQ:ABUS)
DateHeadline
06/24/16 10:12 AMNew Broker Ratings For Arbutus Biopharma Corporation (NASDAQ:ABUS) - FTSE News
06/20/16 02:15 PMThis Weeks Broker Views For Arbutus Biopharma Corporation (NASDAQ:ABUS) - Fiscal Standard
06/08/16 11:20 AMARBUTUS BIOPHARMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement -
06/01/16 07:03 AMArbutus to Present at the 5th Antiviral Drugs Research and Development Conference - [at noodls] - June 1, 2016 First In Vivo Data from Arbutus HBV Preclinical Combination Studies Additive Anti-HBV Effects When Combining Capsid Inhibitor AB-423 with Current Standard of Care VANCOUVER, British Columbia ...
05/28/16 10:37 AMIs Selling Stock Like Arbutus Biopharma Corp After Such Decline Winning Strategy? - HNN - Is Selling Stock Like Arbutus Biopharma Corp After Such Decline Winning Strategy?HNNThe stock of Arbutus Biopharma Corp (NASDAQ:ABUS) is a huge mover today! The stock decreased 3.76% or $0.16 on May 27, hitting $4.1. About 68,004 shares traded hands. Arbutus Biopharma Corp (NASDAQ:ABUS) has declined 29.07% since October ...
05/25/16 01:09 PMARBUTUS BIOPHARMA CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/17/16 12:44 PMArbutus Biopharma Corp. :ABUS-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/16/16 06:39 AMCoverage initiated on Arbutus Biopharma by Chardan Capital Markets -
05/12/16 12:04 PMARBUTUS BIOPHARMA CORP Financials -
05/04/16 08:15 PMEdited Transcript of ABUS earnings conference call or presentation 4-May-16 8:30pm GMT -
05/04/16 03:54 PMArbutus reports 1Q loss -
05/04/16 03:10 PMArbutus Provides Corporate Update and Announces First Quarter 2016 Financial Results - [at noodls] - May 4, 2016 VANCOUVER, British Columbia and DOYLESTOWN, Pa., May 04, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions ...
05/04/16 03:05 PMARBUTUS BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Ex -
05/04/16 12:08 PMQ1 Conference Call: Arbutus Biopharma Corp (NASDAQ:ABUS) - share market updates (press release) - share market updates (press release)Q1 Conference Call: Arbutus Biopharma Corp (NASDAQ:ABUS)share market updates (press release)Shares of Arbutus Biopharma Corp (NASDAQ:ABUS) ended Tuesday session in red amid volatile trading. The shares closed down -0.13 points or -2.70% at $4.69 with 140,808.00 shares getting traded. Post opening the session at $4.75, the shares hit an ...Arbutus Biopharma Corporation (NASDAQ:ABUS) Shorted Shares Decreased By 6.97%B.O.D.Y Confidentialall 3 news articles »
05/04/16 06:07 AMQ1 2016 Arbutus Biopharma Corp Earnings Release - Time Not Supplied -
05/03/16 03:40 PMArbutus Expands HBV Pipeline - [at noodls] - May 3, 2016 VANCOUVER, British Columbia and DOYLESTOWN, Pa., May 03, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virus (HBV) therapeutic solutions ...
05/02/16 01:23 PMTekmira Pharmaceuticals Corporation: Arbutus to Provide a Corporate Update and Release First Quarter 2016 ... - The Wall Street Transcript - Tekmira Pharmaceuticals Corporation: Arbutus to Provide a Corporate Update and Release First Quarter 2016 ...The Wall Street TranscriptVANCOUVER, British Columbia and DOYLESTOWN, Pa., April 29, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will hold a ...Arbutus Biopharma Corporation (ABUS) Updated Broker Price TargetsShare Trading Newsall 2 news articles »
04/29/16 07:18 AMArbutus to Provide a Corporate Update and Release First Quarter 2016 Financial Results - [at noodls] - April 29, 2016 VANCOUVER, British Columbia and DOYLESTOWN, Pa., April 29, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions ...
04/29/16 07:02 AMARBUTUS BIOPHARMA CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
04/27/16 12:24 PMArbutus to Participate in Upcoming Investor Conferences - [at noodls] - April 27, 2016 VANCOUVER, British Columbia and DOYLESTOWN, Pa., April 27, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions ...
04/26/16 01:19 PMBroker Outlook For The Week Ahead Arbutus Biopharma Corporation (ABUS) - Share Trading News - Broker Outlook For The Week Ahead Arbutus Biopharma Corporation (ABUS)Share Trading NewsArbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection ...and more »
04/25/16 01:21 PMARBUTUS BIOPHARMA CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Stateme -
04/24/16 11:48 AMIs Arbutus Biopharma Corp's Fuel For Real? The Stock Just Increased Again - The Post - Is Arbutus Biopharma Corp's Fuel For Real? The Stock Just Increased AgainThe PostThe stock of Arbutus Biopharma Corp (NASDAQ:ABUS) is a huge mover today! The stock increased 5.54% ... different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC.” ...
04/23/16 12:22 PMTekmira Pharmaceuticals Corporation: Arbutus Announces Planned Executive Departure - The Wall Street Transcript - Tekmira Pharmaceuticals Corporation: Arbutus Announces Planned Executive DepartureThe Wall Street TranscriptVANCOUVER, British Columbia and DOYLESTOWN, Pa., April 21, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Patrick T.Arbutus Biopharma Corporation (ABUS) Updated Broker RatingsRisers & FallersArbutus Biopharma Reports Positive Data from Studies of Hepatitis B Drug Candidates; Shares Steady Pre Bell ...Sonoran Weekly ReviewInvestors Are Watching: Arbutus Biopharma Corporation (NASDAQ:ABUS), Endo International plc (NASDAQ:ENDP ...Stock Transcriptall 5 news articles »
04/22/16 12:57 PMArbutus Biopharma Corporation (ABUS) Updated Broker Ratings - Risers & Fallers - Arbutus Biopharma Corporation (ABUS) Updated Broker RatingsRisers & FallersArbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection ...Arbutus Announces Planned Executive DepartureGlobeNewswire (press release)Arbutus Biopharma Reports Positive Data from Studies of Hepatitis B Drug Candidates; Shares Steady Pre Bell ...Sonoran Weekly ReviewInvestors Are Watching: Arbutus Biopharma Corporation (NASDAQ:ABUS), Endo International plc (NASDAQ:ENDP ...Stock Transcriptall 5 news articles »
04/22/16 07:16 AMArbutus Presents Data from Combination Activity Studies of HBV Drug Candidates - [at noodls] - April 22, 2016 Additional Preclinical Combination Data to be Presented This Year Clinical Combination Studies to Begin in 2017 VANCOUVER, British Columbia and DOYLESTOWN, Pa., April 22, 2016 (GLOBE NEWSWIRE) ...
04/21/16 05:33 PMArbutus Announces Planned Executive Departure - [at noodls] - April 21, 2016 VANCOUVER, British Columbia and DOYLESTOWN, Pa., April 21, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions ...
04/14/16 12:29 PMRecently Changed Price Targets On Arbutus Biopharma Corporation (ABUS) - Risers & Fallers - Recently Changed Price Targets On Arbutus Biopharma Corporation (ABUS)Risers & FallersArbutus Biopharma Corp, formerly Tekmira Pharmaceuticals Corporation, is a Canada-based biopharmaceutical company focused on discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the ...Arbutus Biopharma Reports Positive Preclinical Data on Hep B Treatment AB-423; Shares Flat in Pre Market (NASDAQ ...Sonoran Weekly Reviewall 3 news articles »
04/14/16 07:29 AMArbutus Presents Data on HBV Capsid Assembly Inhibitor AB-423 at EASL 2016 - [at noodls] - April 14, 2016 Synergistic Antiviral Activity When Combining AB-423 With Entecavir IND Filing (or Equivalent) Expected in the Second Half of 2016 VANCOUVER, British Columbia and DOYLESTOWN, Pa., April ...
04/11/16 02:45 PMWill Arbutus Biopharma (ABUS) Continue to Surge Higher? -
04/11/16 12:47 PMArbutus Biopharma Corporation (NASDAQ:ABUS) Shorted Shares Decreased By 9.92% - Stock Caller - Arbutus Biopharma Corporation (NASDAQ:ABUS) Shorted Shares Decreased By 9.92%Stock CallerArbutus Biopharma Corp, formerly Tekmira Pharmaceuticals Corporation, is a Canada biopharmaceutical firm focused on discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver ...and more »
04/03/16 11:45 AMNew York Life Investment Management Exits Position in Arbutus Biopharma Corp (ABUS) - Street Edition - New York Life Investment Management Exits Position in Arbutus Biopharma Corp (ABUS)Street EditionArbutus Biopharma Corp formerly Tekmira Pharmaceuticals Corporation is a Canada-based biopharmaceutical company focused on discovering developing and commercializing a cure for patients suffering from chronic hepatitis B infection a disease of the ...and more »
04/02/16 01:18 PMEbola Can Teach Investors an Important Lesson About Economic Viability -
03/31/16 11:43 AMAnalyst Coverage: Arbutus Biopharma Corporation (ABUS) - Risers & Fallers - Analyst Coverage: Arbutus Biopharma Corporation (ABUS)Risers & FallersArbutus Biopharma Corp, formerly Tekmira Pharmaceuticals Corporation, is a Canada-based biopharmaceutical company focused on discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the ...Arbutus Biopharma Declines 4% Despite Acceptance of Abstract Presentation at European Association for the Study of ...Sonoran Weekly Reviewall 5 news articles »
03/31/16 11:43 AMAnalyst Coverage: Arbutus Biopharma Corporation (ABUS) - Risers & Fallers - Analyst Coverage: Arbutus Biopharma Corporation (ABUS)Risers & FallersArbutus Biopharma Corp, formerly Tekmira Pharmaceuticals Corporation, is a Canada-based biopharmaceutical company focused on discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the ...Arbutus Biopharma Declines 4% Despite Acceptance of Abstract Presentation at European Association for the Study of ...Sonoran Weekly Reviewall 5 news articles »
03/30/16 12:53 PMArbutus to Present Preclinical HBV Data at EASL 2016 - [at noodls] - March 30, 2016 VANCOUVER, British Columbia and DOYLESTOWN, Pa., March 30, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions ...
03/30/16 12:41 PM1:41 pm Arbutus Biopharma announces an abstract on ARB-1467, an ongoing Phase II study, for presentation at the EASL 2016 annual meeting; anticipates initiation of clinical combination studies in 2017 -
03/28/16 11:59 AMThis Weeks Broker Price Targets For Arbutus Biopharma Corporation (ABUS) - Share Trading News - This Weeks Broker Price Targets For Arbutus Biopharma Corporation (ABUS)Share Trading NewsArbutus Biopharma Corp, formerly Tekmira Pharmaceuticals Corporation, is a Canada-based biopharmaceutical company focused on discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the ...and more »
03/26/16 11:59 AMAnalyst Coverage Updates - Arbutus Biopharma Corporation (ABUS) - Risers & Fallers - Analyst Coverage Updates - Arbutus Biopharma Corporation (ABUS)Risers & FallersArbutus Biopharma Corp, formerly Tekmira Pharmaceuticals Corporation, is a Canada-based biopharmaceutical company focused on discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the ...Can Arbutus Biopharma Corp's Tomorrow be Different? The Stock Declines AgainClinton Financialall 2 news articles »
03/19/16 10:57 AMRevenue Update on Arbutus Biopharma Corp(NASDAQ:ABUS) - Street Edition - Revenue Update on Arbutus Biopharma Corp(NASDAQ:ABUS)Street EditionArbutus Biopharma Corp formerly Tekmira Pharmaceuticals Corporation is a Canada-based biopharmaceutical company focused on discovering developing and commercializing a cure for patients suffering from chronic hepatitis B infection a disease of the ...Is Arbutus Biopharma Corp a Buy? The Stock Rises AgainRiversideGazette.comall 2 news articles »
03/14/16 09:08 AMArbutus Biopharma Corp. :ABUS-US: Earnings Analysis: Q4, 2015 By the Numbers -
03/14/16 07:59 AMNew Strong Buy Stocks for March 14th -
03/09/16 10:56 AMEarnings Per Share for Arbutus Biopharma Corp (ABUS) Projected to Increase - Franklin Independent - Earnings Per Share for Arbutus Biopharma Corp (ABUS) Projected to IncreaseFranklin IndependentArbutus Biopharma Corp, formerly Tekmira Pharmaceuticals Corporation, is a Canada biopharmaceutical firm focused on discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver ...and more »
03/09/16 10:56 AMTekmira Pharmaceuticals Corporation: Arbutus Announces Year-End 2015 Financial Results - The Wall Street Transcript - Tekmira Pharmaceuticals Corporation: Arbutus Announces Year-End 2015 Financial ResultsThe Wall Street TranscriptVANCOUVER, British Columbia and DOYLESTOWN, Pa., March 09, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus ...and more »
03/09/16 07:00 AMArbutus Announces Year-End 2015 Financial Results - [GlobeNewswire] - VANCOUVER, British Columbia and DOYLESTOWN, Pa., March 09, 2016-- Arbutus Biopharma Corporation, an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus ...
03/08/16 10:52 AMTekmira Pharmaceuticals Corporation: Arbutus Appoints Dr. Elizabeth Howard Executive Vice President and General ... - The Wall Street Transcript - Tekmira Pharmaceuticals Corporation: Arbutus Appoints Dr. Elizabeth Howard Executive Vice President and General ...The Wall Street TranscriptVANCOUVER, British Columbia and DOYLESTOWN, Pa., March 08, 2016 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus ...Updated Price Targets On Arbutus Biopharma Corporation (ABUS)Risers & Fallersall 4 news articles »
03/08/16 07:30 AMArbutus Appoints Dr. Elizabeth Howard Executive Vice President and General Counsel - [GlobeNewswire] - VANCOUVER, British Columbia and DOYLESTOWN, Pa., March 08, 2016-- Arbutus Biopharma Corporation, an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus ...
03/04/16 10:38 AMArbutus Biopharma Corporation (NASDAQ:ABUS) Short Interest Decreased By 17.46% - Stock Caller - Arbutus Biopharma Corporation (NASDAQ:ABUS) Short Interest Decreased By 17.46%Stock CallerArbutus Biopharma Corp, formerly Tekmira Pharmaceuticals Corporation, is a Canada biopharmaceutical firm focused on discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver ...Arbutus Biopharma Corp Rises A lot Today, Is Now One of The Best PerformerRiversideGazette.comall 2 news articles »
03/03/16 10:43 AMArbutus Biopharma Corp Rises A lot Today, Is Now One of The Best Performer - RiversideGazette.com - Arbutus Biopharma Corp Rises A lot Today, Is Now One of The Best PerformerRiversideGazette.comAnalysts await Arbutus Biopharma Corp (NASDAQ:ABUS) to reports earnings on March, 10. They expect $-0.39 ... clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC.” ...Arbutus Biopharma Corporation (NASDAQ:ABUS) Short Interest Decreased By 17.46%Stock Callerall 2 news articles »
02/26/16 10:29 AMArbutus Biopharma Corporation (ABUS) Analyst Updates - Risers & Fallers - Arbutus Biopharma Corporation (ABUS) Analyst UpdatesRisers & FallersArbutus Biopharma Corp, formerly Tekmira Pharmaceuticals Corporation, is a Canada-based biopharmaceutical company focused on discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the ...and more »
About Tekmira Pharmaceuticals Corp

Tekmira Pharmaceuticals Corp logoArbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. Its lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, cccDNA epigenetic modifiers and stimulator of interferon genes agonists.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ABUS
  • CUSIP:
Key Metrics:
  • Previous Close: $3.36
  • 50 Day Moving Average: $3.90
  • 200 Day Moving Average: $4.02
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $183.54M
  • Current Quarter EPS Consensus Estimate: $-1.49 EPS
Additional Links:
Tekmira Pharmaceuticals Corp (NASDAQ:ABUS) Chart for Saturday, June, 25, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha